Urgent liver transplantation for nevirapine-induced acute liver failure: Report of a case and review of the literature

Annals of Transplantation

Volumn 17, Issue 1, 2012, Pages 122-127

  Lopez Delgado, Juan Carlos ^a   Mendiluce, Rafael Mañez ^a   Pinol, Teresa Serrano ^a   Fernández, Xose Pérez ^a   Sanchez, Laura ^a   Vicente, Rosa Granada ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Acute liver failure; Antiretroviral drugs; Immunosuppressive agents; Nevirapine hepatotoxicity; Urgent liver transplantation

Indexed keywords

ABACAVIR; BASILIXIMAB; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; TACROLIMUS; TENOFOVIR; ZIDOVUDINE;

ACUTE LIVER FAILURE; ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LIVER TRANSPLANTATION; PHYSICAL EXAMINATION; THORAX RADIOGRAPHY;

EID: 84859409752     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/aot.882645     Document Type: Article

References (23)

1. Pugh AJ, Barve AJ, Falkner K et al: Drug-induced hepatotoxicity or drug-induced liver injury. Clin Liver Dis, 2009; 13(2): 277-94.
2. Dieterich DT, Robinson PA, Love J, Stern JO: Drug-induced liver injury associated with the use of non nucleoside reverse-transcriptase inhibitors. Clin Infect Dis, 2004; 38(Suppl.2): S80-89.
3. Björnsson E: Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther, 2010; 32(1): 3-13.
4. Núñez M: Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol, 2006; 44(1 Suppl.): S132-39.
5. Maniar JK, Shah SR, Verma R et al: Nevirapineinduced fulminant hepatitis. J Assoc Physicians India, 2006; 54: 957-58.
6. Jao J, Sturdevant M, del Rio Martin J et al: Nevirapine-induced stevens johnson-syndrome and fulminant hepatic failure requiring liver transplantation. Am J Transplant, 2010; 10(7): 1713-16.
7. Patel SM, Johnson S, Belknap SM et al: Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr, 2004; 35: 120-25.
8. Muro E, Droste JA, Hofstede HT et al: Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr, 2005; 39(4): 419-21.
9. Clark SJ, Creighton S, Portmann B et al: Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. J Hepatol, 2002; 36(2): 295-301.
10. Aaskonis M, Masalaite L, Buivydiene A et al: Orthotopic liver transplantation: the first experience and results of the Vilnius University Hospital Santariskiu Klinikos. Ann Transplant, 2010; 15(1): 14-24.
11. van Leth F, Andrews S, Grinsztejn B et al, 2NN study group: The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS, 2005; 19(5): 463-71.
12. Piliero PJ, Purdy B: Nevirapine-induced hepatitis: a case series and review of the literature. AIDS Read, 2001; 11(7): 379-82.
13. Martin AM, Nolan D, James I et al: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS, 2005; 19(1): 97-99.
14. Antela A, Ocampo A, Gómez R et al: Liver toxicity after switching or simplifying to nevirapinebased therapy is not related to CD4 cell counts: results of the TOSCANA study. HIV Clin Trials, 2010; 11(1): 11-17.
15. Rozga J, Malkowski P: Artificial liver support: quo vadis? Ann Transplant, 2010; 15(4): 92-101.
16. Leitze Z, Nadeem A, Choudhary A et al: Manthous, Nevirapine-induced hepatitis treated with corticosteroids. AIDS, 1998; 12: 1115-17.
17. Mens H, Katzenstein TL: Hepatic failure due to nevirapine treatment for HIV infection. Ugeskr Laeger, 2005; 167(46): 4359.
18. Buyse S, Vibert E, Sebagh M et al: Liver transplantation for fulminant hepatitis related to nevirapine therapy. Liver Transpl, 2006; 12(12): 1880-82.
19. Johnson S, Baraboutis JG: Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA, 2000; 284(21): 2723.
20. Teicher E, Vincent I, Bonhomme-Faivre et al: Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet, 2007; 46: 941-52.
21. Frassetto L, Baluom M, Jacobsen W et al: Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virusinfected liver and kidney transplant recipients. Transplantation, 2005; 80: 13-17.
22. Tricot L, Teicher E, Peytavin G et al: Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant, 2009; 9: 1946-52.
23. Mindikoglu AL, Regev A, Magder LS: Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation, 2008; 85: 359-68